Dilation Capital Management LP Purchases Shares of 4,607 Axon Enterprise, Inc $AXON

Dilation Capital Management LP acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, Holdings Channel reports. The institutional investor acquired 4,607 shares of the biotechnology company’s stock, valued at approximately $3,814,000. Axon Enterprise accounts for 2.0% of Dilation Capital Management LP’s portfolio, making the stock its 19th largest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TCI Wealth Advisors Inc. purchased a new stake in shares of Axon Enterprise during the second quarter worth about $214,000. Jaffetilchin Investment Partners LLC boosted its holdings in Axon Enterprise by 11.7% in the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 5,938 shares of the biotechnology company’s stock worth $4,916,000 after buying an additional 624 shares during the last quarter. Vanguard Group Inc. increased its stake in Axon Enterprise by 3.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock worth $7,399,515,000 after buying an additional 305,252 shares in the last quarter. Duncker Streett & Co. Inc. raised its holdings in shares of Axon Enterprise by 3.2% during the second quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock valued at $12,006,000 after acquiring an additional 448 shares during the last quarter. Finally, EFG Asset Management North America Corp. lifted its position in shares of Axon Enterprise by 17.8% in the second quarter. EFG Asset Management North America Corp. now owns 12,701 shares of the biotechnology company’s stock valued at $10,511,000 after acquiring an additional 1,918 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the transaction, the chief financial officer owned 93,592 shares of the company’s stock, valued at $66,813,456.96. This represents a 5.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $743.64, for a total value of $7,436,400.00. Following the transaction, the chief executive officer owned 3,043,982 shares of the company’s stock, valued at approximately $2,263,626,774.48. This represents a 0.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 38,622 shares of company stock valued at $26,439,364. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Trading Up 1.3%

Shares of AXON opened at $540.14 on Friday. Axon Enterprise, Inc has a 12-month low of $469.24 and a 12-month high of $885.91. The firm has a market capitalization of $42.62 billion, a P/E ratio of 133.37, a P/E/G ratio of 29.49 and a beta of 1.45. The firm has a 50-day moving average price of $658.44 and a 200 day moving average price of $726.85. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.45 earnings per share. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on AXON shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Tuesday. Northland Securities set a $800.00 target price on shares of Axon Enterprise in a report on Tuesday, August 5th. Raymond James Financial reissued an “outperform” rating and issued a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Finally, Bank of America increased their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $814.00.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.